These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 16434367)

  • 41. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
    Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
    Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
    Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
    Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
    Panetta JC; Gajjar A; Hijiya N; Hak LJ; Cheng C; Liu W; Pui CH; Relling MV
    Clin Pharmacol Ther; 2009 Dec; 86(6):651-8. PubMed ID: 19741605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
    Yang L; Panetta JC; Cai X; Yang W; Pei D; Cheng C; Kornegay N; Pui CH; Relling MV
    J Clin Oncol; 2008 Apr; 26(12):1932-9. PubMed ID: 18421047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
    Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
    Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On the origin of EEG-slowing and encephalopathy during induction treatment of acute lymphoblastic leukemia.
    Korinthenberg R; Scheuring B; Boos J; Niemeyer C
    Med Pediatr Oncol; 2002 Dec; 39(6):566-72. PubMed ID: 12376979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
    Müller HJ; Löning L; Horn A; Schwabe D; Gunkel M; Schrappe M; von Schütz V; Henze G; Casimiro da Palma J; Ritter J; Pinheiro JP; Winkelhorst M; Boos J
    Br J Haematol; 2000 Aug; 110(2):379-84. PubMed ID: 10971395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
    Gentili D; Conter V; Rizzari C; Tschuemperlin B; Zucchetti M; Orlandoni D; D'Incalci M; Masera G
    Ann Oncol; 1996 Sep; 7(7):725-30. PubMed ID: 8905031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia.
    Semeraro N; Montemurro P; Giordano P; Schettini F; Santoro N; De Mattia D; Giordano D; Conese M; Colucci M
    Thromb Haemost; 1990 Aug; 64(1):38-40. PubMed ID: 2274927
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study.
    Würthwein G; Lanvers-Kaminsky C; Gerss J; Möricke A; Zimmermann M; Stary J; Smisek P; Attarbaschi A; Nath C; Zucchetti M; Rizzari C; Schrappe M; Boos J;
    Ther Drug Monit; 2020 Jun; 42(3):435-444. PubMed ID: 32022785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
    Rizzari C; Zucchetti M; Conter V; Diomede L; Bruno A; Gavazzi L; Paganini M; Sparano P; Lo Nigro L; Aricò M; Milani M; D'Incalci M
    Ann Oncol; 2000 Feb; 11(2):189-93. PubMed ID: 10761754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
    Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
    J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
    Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
    J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
    Vyas C; Jain S; Kapoor G; Mehta A; Takkar Chugh P
    Pediatr Hematol Oncol; 2018; 35(5-6):331-340. PubMed ID: 30488741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
    Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
    Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.
    Matsuzaki A; Suminoe A; Hara T
    Pediatr Hematol Oncol; 2002 Dec; 19(8):601-3. PubMed ID: 12487838
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients.
    Wu J; Chen C; Huang S; Shen S; Chen J; Zhang S
    Technol Cancer Res Treat; 2020; 19():1533033820980113. PubMed ID: 33287663
    [TBL] [Abstract][Full Text] [Related]  

  • 60. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
    Tong WH; Pieters R; Hop WC; Lanvers-Kaminsky C; Boos J; van der Sluis IM
    Pediatr Blood Cancer; 2013 Feb; 60(2):258-61. PubMed ID: 22961784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.